Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · IEX Real-Time Price · USD
35.55
-0.16 (-0.45%)
At close: Jul 19, 2024, 4:00 PM
35.45
-0.10 (-0.28%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Protagonist Therapeutics Employees
Protagonist Therapeutics had 112 employees as of December 31, 2023. The number of employees increased by 7 or 6.67% compared to the previous year.
Employees
112
Change (1Y)
7
Growth (1Y)
6.67%
Revenue / Employee
$2,812,080
Profits / Employee
$1,447,411
Market Cap
2.09B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 112 | 7 | 6.67% |
Dec 31, 2022 | 105 | -13 | -11.02% |
Dec 31, 2021 | 118 | 39 | 49.37% |
Dec 31, 2020 | 79 | 6 | 8.22% |
Dec 31, 2019 | 73 | 9 | 14.06% |
Dec 31, 2018 | 64 | 9 | 16.36% |
Dec 31, 2017 | 55 | 20 | 57.14% |
Dec 31, 2016 | 35 | 6 | 20.69% |
Dec 31, 2015 | 29 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
BrightSpring Health Services | 35,000 |
Addus HomeCare | 34,846 |
LifeStance Health Group | 9,325 |
Premier | 2,800 |
10x Genomics | 1,259 |
STAAR Surgical Company | 1,115 |
Beam Therapeutics | 507 |
Rocket Pharmaceuticals | 268 |
PTGX News
- 49 minutes ago - Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 - Accesswire
- 7 weeks ago - Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 - Accesswire
- 2 months ago - Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress - Accesswire
- 2 months ago - Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event - Accesswire
- 2 months ago - Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update - Accesswire
- 4 months ago - Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data - Accesswire
- 4 months ago - Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - Accesswire
- 4 months ago - Protagonist Therapeutics to Participate in Upcoming Investor Conferences - Accesswire